Espironolactona [INN-Spanish] en es it fr

Espironolactona [INN-Spanish] Brand names, Espironolactona [INN-Spanish] Analogs

Espironolactona [INN-Spanish] Brand Names Mixture

  • No information avaliable

Espironolactona [INN-Spanish] Chemical_Formula


Espironolactona [INN-Spanish] RX_link

Espironolactona [INN-Spanish] fda sheet

Espironolactona_[INN-Spanish] FDA

Espironolactona [INN-Spanish] msds (material safety sheet)

Espironolactona_[INN-Spanish] MSDS

Espironolactona [INN-Spanish] Synthesis Reference

No information avaliable

Espironolactona [INN-Spanish] Molecular Weight

514.617 g/mol

Espironolactona [INN-Spanish] Melting Point


Espironolactona [INN-Spanish] H2O Solubility

Practically insoluble

Espironolactona [INN-Spanish] State


Espironolactona [INN-Spanish] LogP


Espironolactona [INN-Spanish] Dosage Forms


Espironolactona [INN-Spanish] Indication

For the treatment of hypertension.

Espironolactona [INN-Spanish] Pharmacology

Telmisartan is an orally active nonpeptide angiotensin II antagonist that acts on the AT1 receptor subtype. New studies suggest that telmisartan may also have PPARγ agonistic properties that could potentially confer beneficial metabolic effects. This observation is currently being explored in clinical trials. Angiotensin II is formed from angiotensin I in a reaction catalyzed by angiotensin-converting enzyme (ACE, kininase II). Angiotensin II is the principal pressor agent of the renin-angiotensin system, with effects that include vasoconstriction, stimulation of synthesis and release of aldosterone, cardiac stimulation, and renal reabsorption of sodium. Telmisartan works by blocking the vasoconstrictor and aldosterone secretory effects of angiotensin II.

Espironolactona [INN-Spanish] Absorption

Absolute bioavailability depends on dosage. Food slightly decreases the bioavailability (a decrease of about 6% is seen when the 40-mg dose is administered with food).

Espironolactona [INN-Spanish] side effects and Toxicity

Intravenous LD50 in rats is 150-200 mg/kg in males and 200 to 250 mg/kg in females. Acute oral toxicity is low: no deaths and no changes occurred in rats or dogs at 2000 mg/kg, the highest dose tested. Limited data are available with regard to overdosage in humans. The most likely manifestations of overdosage with telmisartan would be hypotension, dizziness and tachycardia; bradycardia could occur from parasympathetic (vagal) stimulation.

Espironolactona [INN-Spanish] Patient Information

Espironolactona [INN-Spanish] Organisms Affected

Humans and other mammals